Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb23104 · 1 trial · 16 indications
Safety and tolerability
| Arm | Type | Description |
|---|---|---|
| XmAb®23104 Monotherapy | EXPERIMENTAL | XmAb®23104 administered by IV dosing on Days 1 and 15 of each 28-day cycle x 2 cycles |
| XmAb®23104 Combination Therapy with Ipilimumab | EXPERIMENTAL | XmAb®23104 administered by IV on Days 1 and 15 of each 28-day cycle x 2 cycles + Yervoy® (ipilimumab) |
| Name | Type | Description |
|---|---|---|
| XmAb®23104 | BIOLOGICAL | Monoclonal bispecific antibody |
| Yervoy® (ipilimumab) | BIOLOGICAL | Monoclonal antibody |
Inclusion Criteria: 1. Subjects in Part A (dose escalation) must have a diagnosis of any of the following: Histologically or cytologically confirmed advanced solid tumors, including the following: 1. Melanoma (excluding uveal melanoma) 2. Cervical carcinoma 3. Pancreatic carcinoma 4...
XmAb23104 is an investigational monoclonal antibody developed by Xencor, Inc. for the treatment of advanced solid tumors. It is being studied in oncology, with melanoma (excluding uveal melanoma) as a listed indication. It remains in clinical development and is not an approved therapy.
XmAb23104 is being studied in melanoma excluding uveal melanoma, along with other advanced solid tumors. It is an investigational agent in Phase 1 development and has not been approved for any indication. Its melanoma evaluation occurred within a single completed Phase 1 trial.
XmAb23104 targets ICOS, an inducible T cell costimulatory receptor that belongs to the checkpoint target class. By binding ICOS, the monoclonal antibody is designed to act on a costimulatory pathway involved in T cell activation. Xencor engineered the molecule as an investigational oncology therapeutic.
Xencor, Inc. (ticker XNCR) is the developer of XmAb23104. The company designed the monoclonal antibody and sponsored its clinical evaluation in advanced solid tumors. XmAb23104 is also written as XmAb®23104.
XmAb23104 is in Phase 1 development. It is an investigational monoclonal antibody and has not been approved by the FDA for any indication. Its clinical program consists of one completed Phase 1 trial, and no trials are currently active.
XmAb23104 was evaluated in the Phase 1 DUET-3 study, NCT03752398, titled A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors. The trial enrolled 198 participants across sites in the United States and is completed. It was randomized and controlled, with biomarker-selected enrollment.
Yes, XmAb23104 and XmAb®23104 refer to the same investigational monoclonal antibody from Xencor, Inc. The registered trademark symbol appears in the compound's formal styling and in the title of its Phase 1 DUET-3 trial, NCT03752398. Both names identify the same ICOS-targeted agent.